Asco20 - Kras Wild-Type Pancreatic Cancer

ASCO20 - KRAS Wild-Type Pancreatic Cancer

HPR

Voice of Pancreatic Cancer Podcast - Targeting the KRAS mutation for more effective cancer treatment

Seena Magowitz Foundation

Personalized treatment approaches for patients with KRAS-mutant pancreatic cancer

Restoration of Wild-Type TP53 in Pancreatic Cancer | Aging-US

Aging (Aging-US)

Improving outcomes in KRAS-mutant pancreatic cancer

The future of precision oncology in pancreatic cancer

NRG1 Fusions and KRAS Wild-Type PDAC: What You Need To Know

Precision Oncology and Biomarker Testing

Dr. Skoulidis and Terri Conneran Discuss Treatment Strategy for Lung, Colon, and Pancreatic Cancers

Targeted Therapy for Pancreatic Ductal Adenocarcinoma

Medical College of Wisconsin

Targeted therapies for personalized medicine in pancreatic cancer

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer | Oncotarget

Advances in KRAS G12D-targeted therapy for pancreatic cancer

Dr. Gius - Sirt2 Regulation of KRAS is an Early Event in Pancreas Carcinogenesis

HirshbergFoundation

The emerging roles of NGS and liquid biopsies in pancreatic cancer

“Is KRAS Druggable?” Experts in Pancreatic Cancer and KRAS Discuss Tough Questions

Pancreatic Cancer Action Network

CodeBreak100: assessing sotorasib in patients with KRAS p.G12C-mutant pancreatic cancer

Assessing the heterogeneity of KRAS-mutant pancreatic adenocarcinomas

ICAHO20 - ASCO Direct™ Highlights - Dr. Andrew Coveler - Pancreatic Cancer

Binaytara Foundation

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure | RTCL.TV

CtDNA KRAS Mutation Levels and Outcomes in Non-Resectable Pancreatic Cancer

Targeted Oncology